Clinical Trial Update: Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This item provides an update on a Phase 2 clinical trial evaluating Paclitaxel in patients with recurrent or refractory non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Lung Cancer | Phase 2 | Status: UNKNOWN